Compound Summary
Compound Information
Spiroxatrine
Compound Name: | Spiroxatrine |
Compound CID: | 5268 |
Synonyms: | Spiroxatrine 1054-88-2 Spiroxatrinum Spiroxatrine (R 5188) R 5188 More... |
Iupac Name: | 8-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one |
InChI: | InChI=1S/C22H25N3O3/c26-21-22(25(16-23-21)17-6-2-1-3-7-17)10-12-24(13-11-22)14-18-15-27-19-8-4-5-9-20(19)28-18/h1-9,18H,10-16H2,(H,23,26) |
InChIKey: | JVGBTTIJPBFLTE-UHFFFAOYSA-N |
Canonical Smiles: | C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CC4COC5=CC=CC=C5O4 |
Isomeric Smiles: | C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CC4COC5=CC=CC=C5O4 |
Molecular Weight: | 379.5 |
Molecular Formula: | C22H25N3O3 |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
Spiroxatrine
Molecular Weight: | 379.5 |
Molecular Formula: | C22H25N3O3 |
Hydrogen Bond Donor Count: | 1 |
Hydrogen Bond Acceptor Count: | 5 |
Rotatable Bond Count: | 3 |
Heavy Atom Count: | 28 |
Complexity: | 557 |
Synonyms
Spiroxatrine
| Spiroxatrine | Spiroxatrine |
|---|---|
Spiroxatrine |
1054-88-2 |
Spiroxatrinum |
Spiroxatrine (R 5188) |
R 5188 |
SPIROXAMIDE |
8-(2,3-Dihydro-1,4-benzodioxin-2-yl)methyl-1-phenyl-1,3,8-triazaspiro4,5decan-4-one |
CHEMBL300555 |
NSC665322 |
NCGC00015908-05 |
DSSTox_CID_25198 |
DSSTox_RID_80744 |
DSSTox_GSID_45198 |
Spiroxatrine INN |
Espiroxatrina |
Spiroxatrinum INN-Latin |
8-(2,3-Dihydro-1,4-benzodioxin-2-ylmethyl)-1-phenyl-1,3,8-triazaspiro4.5decan-4-one |
Espiroxatrina INN-Spanish |
CAS-1054-88-2 |
SR-01000075579 |
NSC 665322 |
Biomol-NT_000104 |
GTPL53 |
Lopac0_001142 |
BPBio1_001395 |
SCHEMBL1255303 |
DTXSID3045198 |
SCHEMBL23326247 |
CHEBI:91845 |
HMS2089G17 |
HMS3263F05 |
HMS3266D15 |
HMS3411K18 |
HMS3675K18 |
Tox21_110260 |
Tox21_501142 |
BDBM50020192 |
AKOS024458589 |
Tox21_110260_1 |
CCG-205216 |
LP01142 |
NSC-665322 |
SDCCGSBI-0051109.P002 |
1,3,8-Trianaspiro(4.5)decane-4-one,8-(1,4-benzodioxan-2-ylmethyl)-1-phenyl- |
8-(1,4-Benzodioxan-2-ylmethyl)-1-phenyl-1,3,8-trianaspiro(4,5)decane-4-one |
8-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-4-phenyl-2,4,8-triazaspiro4.5decan-1-one |
NCGC00015908-03 |
NCGC00015908-04 |
NCGC00015908-06 |
NCGC00015908-07 |
NCGC00015908-08 |
NCGC00015908-09 |
NCGC00024696-02 |
NCGC00024696-03 |
NCGC00024696-04 |
NCGC00024696-05 |
NCGC00261827-01 |
NCI60_022532 |
DB-108293 |
EU-0101142 |
S-103 |
L001271 |
J-001433 |
Q6592066 |
SR-01000075579-1 |
SR-01000075579-3 |
BRD-A72483914-001-01-1 |
BRD-A72483914-001-02-9 |
8-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-phenyl-1,3,8-triazaspiro4.5decan-4-one |
8-(2,3-Dihydro-benzo1,4dioxin-2-ylmethyl)-1-phenyl-1,3,8-triaza-spiro4.5decan-4-one |
8-((2,3-Dihydrobenzob1,4dioxin-2-yl)methyl)-1-phenyl-1,3,8-triazaspiro4.5decan-4-one |
Experimental Data
Spiroxatrine
| Species | Dosage | Unit | CG Lifespan(AVG/MED days) | TG Lifespan(AVG/MED days) | Lifespan Change(AVG/MED%) | CG Lifespan(MAX days) | TG Lifespan(MAX days) | Lifespan Change(MAX%) | Significant | Strain | Gender | PubMed | Active Label |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33 | umol/L | 14 | NS | N2 | 24134630 | Inactive |
Experimental Data Visualization
Spiroxatrine
Statistics Data
Spiroxatrine
| Species | Lifespan Change(AVG/MED%) | Lifespan Change(MAX%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | 14 | 1 | 1 |
Statistics Data Visualization
Spiroxatrine
